EWTX Form 4: Blaustein receives 17,500 RSUs and 105,000 options

Rhea-AI Filing Summary

Edgewise Therapeutics insider grant: The company reported that Robert Blaustein, Chief Development Officer and director, was granted 17,500 restricted stock units (RSUs) and options to purchase 105,000 shares on 08/12/2025. The RSUs are payable one-for-one upon vesting in four equal annual installments beginning 08/12/2026. The options have an exercise price of $13.39, vest at 1/48th monthly beginning 09/12/2025, and expire 08/12/2035. Following these grants Blaustein beneficially owns 17,500 RSUs and 105,000 option shares directly. The filing was signed by John R. Moore under power of attorney on 08/14/2025.

Positive

• Time-based RSUs and options align executive incentives with long-term company performance
• Clear vesting schedules (RSUs vest in four equal annual installments; options vest monthly) reduce near-term turnover risk
• Full disclosure of exercise price ($13.39), vesting commencement, and expiration dates

Negative

• Potential dilution from 122,500 share-equivalents if RSUs vest and options are exercised
• No outstanding share count provided in this filing, so dilution percentage cannot be assessed from this document alone

Insights

Corporate Governance Expert

TL;DR: Typical executive equity grants for retention; clear multi-year vesting aligns executive incentives with long-term shareholder value.

The grants consist of time-based RSUs and options with standard 4-year and monthly vesting schedules, respectively. The use of both RSUs and options balances immediate equity alignment with upside performance incentives via options. The exercise price of $13.39 sets a concrete strike for potential future dilution if exercised. Documentation is complete and includes vesting commencement and expiration dates.

Securities Analyst

TL;DR: Transaction is routine insider compensation; materiality to valuation depends on company share count but appears non-disruptive on its face.

The filing reports insider awards totaling 122,500 share-equivalents. The option term to 2035 is standard for long-dated incentives. Investors should note the exact outstanding share base to quantify dilution; the filing does not provide that figure. All items are directly beneficially owned by the reporting person and properly disclosed under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blaustein Robert

(Last) (First) (Middle)

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	08/12/2025		A		17,500		(1)	08/12/2035	Common Stock	17,500	$0.00	17,500	D
Stock Options (Right to buy)	$13.39	08/12/2025		A		105,000		(2)	08/12/2035	Common Stock	105,000	$0.00	105,000	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

2. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	John R. Moore, by POA from Robert Blaustein	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Robert Blaustein receive according to the Form 4 for EWTX?

The Form 4 reports 17,500 RSUs and options to purchase 105,000 shares granted on 08/12/2025.

When do the RSUs and options vest for EWTX insider grants?

RSUs vest in four equal annual installments beginning 08/12/2026. Options vest at 1/48th per month beginning 09/12/2025.

What is the exercise price and expiration for the options granted to the EWTX officer?

The options have an exercise price of $13.39 and an expiration date of 08/12/2035.

Does the filing show whether the reporting person owns the shares directly or indirectly?

The filing indicates direct beneficial ownership of the reported RSUs and options following the transaction.

Who signed the Form 4 for Robert Blaustein?

The Form 4 was signed by John R. Moore by power of attorney on 08/14/2025.